Organon & Co. Capital Expenditures
Organon & Co. (OGN) reported Capital Expenditures of $79.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-07-31
- Organon & Co. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $42.00M, a 7.69% increase year-over-year.
- Organon & Co. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $37.00M, a 15.63% increase year-over-year.
- Organon & Co. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $45.00M, a 18.18% decline year-over-year.
- Organon & Co. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $46.00M, a 9.52% increase year-over-year.
- Organon & Co. payments to acquire property, plant, and equipment for fiscal 2025 was $162.00M, a 7.43% decline from fiscal 2024.
- Organon & Co. payments to acquire property, plant, and equipment for fiscal 2024 was $175.00M, a 30.28% decline from fiscal 2023.
- Organon & Co. payments to acquire property, plant, and equipment for fiscal 2023 was $251.00M, a 28.06% increase from fiscal 2022.
- Organon & Co. payments to acquire property, plant, and equipment for fiscal 2022 was $196.00M, a 2.08% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $79.00M 10-Q · filed 2026-07-31 | $124.00M derived: sum of 3 quarters · filed 2026-07-31 | $170.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $37.00M 10-Q · filed 2026-05-04 | $82.00M derived: sum of 2 quarters · filed 2026-05-04 | $128.00M derived: sum of 3 quarters · filed 2026-05-04 | $167.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $45.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $91.00M derived: sum of 2 quarters · filed 2026-02-24 | $130.00M derived: sum of 3 quarters · filed 2026-07-31 | $162.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $46.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $85.00M derived: sum of 2 quarters · filed 2026-07-31 | $117.00M 10-Q · filed 2025-11-10 | $172.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $39.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $71.00M 10-Q · filed 2026-07-31 | $126.00M derived: sum of 3 quarters · filed 2026-07-31 | $168.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $32.00M 10-Q · filed 2026-05-04 | $87.00M derived: sum of 2 quarters · filed 2026-05-04 | $129.00M derived: sum of 3 quarters · filed 2026-05-04 | $161.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $55.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $97.00M derived: sum of 2 quarters · filed 2026-02-24 | $129.00M derived: sum of 3 quarters · filed 2026-02-24 | $175.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $42.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $74.00M derived: sum of 2 quarters · filed 2025-11-10 | $120.00M 10-Q · filed 2025-11-10 | $199.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $78.00M 10-Q · filed 2025-08-06 | $157.00M derived: sum of 3 quarters · filed 2026-02-24 | $212.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $46.00M 10-Q · filed 2025-05-02 | $125.00M derived: sum of 2 quarters · filed 2026-02-24 | $180.00M derived: sum of 3 quarters · filed 2026-02-24 | $251.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $134.00M derived: sum of 2 quarters · filed 2026-02-24 | $205.00M derived: sum of 3 quarters · filed 2026-02-24 | $251.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $55.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $126.00M derived: sum of 2 quarters · filed 2024-11-01 | $172.00M 10-Q · filed 2024-11-01 | $235.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $71.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $117.00M 10-Q · filed 2024-08-07 | $180.00M derived: sum of 3 quarters · filed 2025-11-10 | $235.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $46.00M 10-Q · filed 2024-05-03 | $109.00M derived: sum of 2 quarters · filed 2025-11-10 | $164.00M derived: sum of 3 quarters · filed 2025-11-10 | $209.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $63.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $118.00M derived: sum of 2 quarters · filed 2025-11-10 | $163.00M derived: sum of 3 quarters · filed 2025-11-10 | $196.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $55.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $100.00M derived: sum of 2 quarters · filed 2023-11-03 | $133.00M 10-Q · filed 2023-11-03 | $192.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $78.00M 10-Q · filed 2023-08-09 | $137.00M derived: sum of 3 quarters · filed 2024-02-26 | $173.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $33.00M 10-Q · filed 2023-05-05 | $92.00M derived: sum of 2 quarters · filed 2024-02-26 | $128.00M derived: sum of 3 quarters · filed 2024-02-26 | $187.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $59.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $95.00M derived: sum of 2 quarters · filed 2024-02-26 | $154.00M derived: sum of 3 quarters · filed 2024-02-26 | $192.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $36.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $95.00M derived: sum of 2 quarters · filed 2022-11-04 | $133.00M 10-Q · filed 2022-11-04 | $254.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $59.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $97.00M 10-Q · filed 2022-08-05 | $218.00M derived: sum of 3 quarters · filed 2023-02-27 | $265.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $38.00M 10-Q · filed 2022-05-06 | $159.00M derived: sum of 2 quarters · filed 2023-02-27 | $206.00M derived: sum of 3 quarters · filed 2023-02-27 | |
| 2020-12-31 | $121.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $168.00M derived: sum of 2 quarters · filed 2023-02-27 | $255.00M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $47.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $134.00M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $87.00M 10-Q · filed 2021-08-16 | |||
| 2019-12-31 | $92.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |